Concluding Thoughts on Ph+ ALL Treatment

EP: 1.Overview of Characteristics Unique to Ph+ ALL

EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL

EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

EP: 4.Screening and Diagnosing of Ph+ ALL in Adults

EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management

EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL

EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients

EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients

EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care

EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL

EP: 11.Disparities in Access to Care for Ph+ ALL patients

EP: 12.The Future of Ph+ ALL Treatments

Now Viewing

EP: 13.Concluding Thoughts on Ph+ ALL Treatment

This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.

In conclusion, Dr Abbas stressed engaging community practices more in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) care while ensuring specialist leadership and optimal up-front therapy access. Dr Jabbour highlighted immense survival gains from 10% to 90% in recent years, with cures becoming reality now—not just ideals for the future. Equity in access to best available treatments remains vital. Dr McCloskey advised rethinking outdated potent toxicity perceptions given new safety data enabling more appropriate patient selection. Robust measurable residual disease monitoring must inform Ph+ ALL management everywhere. Dr Ebot-Tar discussed payers balancing innovation support, value demonstration to stakeholders, and personalized care. Ongoing collaboration between specialties and health plans can continue progress.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.